Home / Health / Obesity Drugs: Europe's Coverage Gap
Obesity Drugs: Europe's Coverage Gap
16 Jun
Summary
- US leads in obesity medication use; Europe lags in coverage.
- Obesity drug market to reach $173.5bn by 2031 in major markets.
- Integrating medication with complementary care boosts patient outcomes.
As of June 16, 2026, the United States leads in the utilization of obesity medications, particularly GLP-1 receptor agonists (GLP-1RAs). In contrast, Europe's coverage for these treatments lags, with only 2-3% of eligible patients treated compared to 10% in the US. This disparity highlights an opportunity for European healthcare systems to improve integration of medication with complementary care.
The global obesity therapeutic market is anticipated to generate sales of $173.5 billion across seven major markets by 2031. Despite the transformative potential of obesity drugs, akin to bariatric surgery outcomes, societal stigma surrounding the condition persists. This stigma affects both patients and healthcare professionals, sometimes leading to treatment discontinuation.
Experts at the HLTH Europe 2026 conference discussed the need to reframe obesity as a chronic metabolic disease, moving past its perception as a lifestyle choice. Germany's legal framework still categorizes obesity as a lifestyle choice, unlike Italy, which recently legislated it as a chronic illness.
Integrating medication with wraparound care is seen as a key strategy for Europe to maximize the value of obesity treatments. Real-world evidence suggests a combined behavioral and pharmaceutical approach can yield superior weight loss results. Addressing systemic changes, care models, and sustainability will be critical for widespread adoption and to ensure a significant societal return on investment.
